重组人血管内皮抑制素联合伊立替康和洛铂治疗晚期复发小细胞肺癌的临床观察 点击下载
| 论文标题： | 重组人血管内皮抑制素联合伊立替康和洛铂治疗晚期复发小细胞肺癌的临床观察 |
| 英文标题： | |
| 中文摘要： | 目的：观察重组人血管内皮抑制素联合洛铂和伊立替康治疗晚期复发小细胞肺癌（SCLC）的临床疗效及安全性。方法：将我院收治的晚期复发SCLC患者88例，按照随机数字表法分为对照组（41例）和观察组（47例）。对照组患者给予伊立替康注射液+注射用洛铂治疗。观察组患者在对照组基础上加用重组人血管内皮抑制素注射液15 mg加入0.9％氯化钠注射液250 mL中，ivgtt，qd，持续14 d，间隔14 d。 28 d为1个周期，两组患者均治疗2个周期。观察两组患者临床疗效、治疗前后血清癌胚抗原（CEA）水平、体力状态（ECOG）和生存质量（QOL）评分。并比较两组患者生存情况及不良反应发生情况。结果：观察组患者总有效率为59.6％，高于对照组的43.9％，但差异无统计学意义（P＞0.05）。治疗前，两组患者血清CEA水平及ECOG和QOL评分比较，差异均无统计学意义（P＞0.05）；治疗后，两组患者血清CEA水平均较治疗前显著降低，且观察组显著低于对照组，差异均有统计学意义（P＜0.05）；观察组患者ECOG评分显著降低、QOL评分较治疗前显著升高，且显著优于对照组，差异均有统计学意义（P＜0.05）。观察组患者总生存期（OS）为16.8个月，显著高于对照组的11.5个月，差异有统计学意义（P＜0.05）。观察组患者血小板下降发生率显著高于对照组，白细胞下降、肝功能异常的发生率均显著低于对照组，差异均有统计学意义（P＜0.05）。结论：重组人血管内皮抑制素联合伊立替康和洛铂能改善患者血清CEA水平和患者生存质量，延长生存时间。 |
| 英文摘要： | OBJECTIVE： To observe the clinical efficacy and safety of recombinant human endostatin （rh-endostatin） combined with Lobaplatin for injection and irinotecan injection in the treatment of advanced recurrent small cell lung cancer （SCLC）. METHODS： A total of 88 patients with advanced recurrent SCLC in our hospital were divided into control group （41 cases） and observation group （47 cases） according to random number table. Control group was given Irinotecan injection+Lobaplatin for injection. Observation group was additionally given Recombinart human endostatin injection 15 mg added into 0.9％ Sodium chloride injection 250 mL， ivgtt， qd， for consecutive 14 d， every 14 d. A treatment course lasted for 28 d， and both groups were treated for 2 courses. The clinical efficacy， the levels of serum carcinoembryonic antigen （CEA）， the scores physical state （ECOG） and quality of life （QOL） before， after treatment were observed in the two groups， and the survival and adverse reactions of the two groups were compared. RESULTS： The total response rate of observation group was 59.6％， which was higher than 43.9％ of control group， but there was no statistical significance （P＞0.05）. Before treatment， there was no significant difference in serum CEA levels， ECOG scores or QOL scores，between 2 groups （P＞0.05）； after treatment， the serum CEA levels of the two groups were significantly decreased， and the observation group was significantly lower than the control group， with statistically significant （P＜0.05）. In observation group， ECOG scores decreased while QOL scores increased significantly， and significantly better than the control group， with statistical significance （P＜0.05）. The overall survival （OS） of observation group was 16.8 months， which was significantly higher than 11.5 months of control group， with statistical significance （P＜0.05）. The incidence of leucopenia in observation group was significantly higher than control group； the incidence of leucopenia and abnormal liver function were significantly lower than control group， with statistical significance （P＜0.05）. CONCLUSIONS： Rh-endostatin injection combined with lobaplatin and irinotecan can improve serum CEA levels and the quality of living aswell as prolong the survival time. |
| 期刊： | 2017年第28卷第20期 |
| 作者： | 肖铟，刘沫然，徐忠玲，郑广，王英 |
| 英文作者： | XIAO Yin，LIU Moran，XU Zhongling，ZHEN Guang，WANG Ying |
| 关键字： | 伊立替康；洛铂；重组人血管内皮抑制素；小细胞肺癌；复发 |
| KEYWORDS： | Irinotecan； Lobaplatin； Recombinant human endostatin； Small cell lung cancer； Recurrence |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！